Portfolio Snapshot
Strategic Investments Across the Healthcare Value Chain
Hiranandani & Wang's portfolio reflects a diverse yet tightly integrated set of investments across the regenerative medicine and diagnostic sectors. Each company in the portfolio plays a unique role within the healthcare ecosystem, enabling synergy across R&D, production, clinical application, and distribution.
01
Cell 101 serves as the clinical and scientific foundation for H&W’s regenerative medicine initiatives. It focuses on stem cell research and development, intellectual property generation, and academic collaborations that feed into clinical practice and product innovation.
02
Meta Pharma is a hybrid B2B/B2C provider specializing in stem cell therapy. It acts as a core distribution and sales partner, supporting product rollout, expanding market reach, and ensuring therapeutic adoption across hospitals, clinics, and pharmacies.
03
Bio Genx is the production and logistics arm, focused on scalable manufacturing and export-ready infrastructure for stem cell products. It also engages in structured procurement models and co-development of new IP in partnership with H&W.
04
Nuclear Medicine (India) represents H&W’s diagnostic and theranostic investments, offering capabilities in advanced imaging and targeted therapy that complement the firm’s broader commitment to precision medicine.
01
Cell 101
-
Acting as our clinical and scientific partner across all programs.
-
Co-developing therapy protocols and application science.
-
Providing training and certification to doctors handling regenerative therapies.
-
Supporting pilot treatments, patient data collection, and continuous product feedback.
-
Facilitating R&D and academic partnerships across institutions.
02
Meta Pharma
-
Core distribution and sales partner.
-
Supporting expansion of pharma salesforce and digital reach.
-
Handling nationwide and regional rollout of products.
-
Assisting in product registration and market entry strategies.
-
Bridging therapies to end-users via hospitals, clinics, and pharmacies.
03
Bio Genx
-
Committing capital for bulk procurement of stem cells under
structured tiered pricing. -
Strategic partnership enables joint development and shared usage of new IP.
-
Full quality oversight with Certificates of Analysis (COAs) and
third-party testing. -
Leveraging our distribution network for regional and global market access.
04
Nuclear Medicine(India)
-
Serving as our core investment in the field of diagnostic and theranostic healthcare, with a focus on precision imaging and targeted therapy.
-
Supporting the development and operation of advanced diagnostic centers equipped with radiopharmaceutical technologies for early and accurate disease detection.
-
Enhancing capabilities in molecular imaging and personalized treatment, especially in oncology, through strategic integration of diagnostics and therapy.
Value-Add Capabilities
01
M&A
We provide end-to-end support in identifying acquisition targets, structuring deals, and ensuring smooth post-merger integration—helping companies grow through smart, strategic consolidation.
02
Scientific Edge
Our access to advanced labs, top-tier researchers, and proprietary research IP allows us to add technical depth and innovation credibility to the ventures we back.
03
Market Access
We open doors to established networks of clinics, hospitals, and healthcare distributors across Asia and the UK, enabling faster and broader product penetration.
04
Capital Planning
We guide our partners through fundraising, IPO readiness, and compliance strategy, ensuring they are well-positioned for long-term financial sustainability and scalable growth.
01
Active Partnership Model (5–7 Years)
We engage deeply with each portfolio company over a long-term horizon, providing continuous strategic, operational, and financial support to ensure sustainable growth and maturity.
02
Support Across R&D, Compliance, Distribution, and IP Licensing
Our involvement goes beyond capital. We actively assist with research and development, regulatory compliance, go-to-market strategy, and managing intellectual property assets to maximize value creation.
03
Exit via Strategic Sale, IPO, or Institutional Secondary
We align early on with founders to plan scalable and profitable exit routes—whether through acquisition, public listing, or structured secondary deals—ensuring returns for all stakeholders and continuity for the business.